Titre :

Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.

Auteur(s) :

Thiebaut, Mathilde [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Riviere, Sebastien [Auteur]
Mahevas, Thibaut [Auteur]
Bellakhal, Syrine [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Fain, Olivier [Auteur]
Mekinian, Arsene [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]

Titre de la revue :

Autoimmunity Reviews

Nom court de la revue :

Autoimmun. Rev.

Numéro :

17

Pagination :

582-587

Date de publication :

2018-06

Mot(s)-clé(s) :

Rituximab
Interstitial lung disease
Systemic sclerosis

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objective: To describe safety and efficacy of rituximab in patients with systemic sclerosis. Methods: We included 13 patients with systemic sclerosis treated with rituximab and pooled with 40 additional patients from the ...
Lire la suite >Objective: To describe safety and efficacy of rituximab in patients with systemic sclerosis. Methods: We included 13 patients with systemic sclerosis treated with rituximab and pooled with 40 additional patients from the literature. SSc rituximab untreated patients were matched to rituximab treated ones. Results: Thirteen patients who received rituximab and 26 rituximab-untreated patients were included. In comparison to 26 patients who did not received rituximab, FVC changes were not significantly different, whereas DLCO improved in 13 patients who received rituximab (0 [−4; 4] vs loss of −7 [−19; 0]; p = 0.05). Considering 7 rituximab treated and 14 untreated diffuse SSc, FVC was improved during the 24 [12; 46] months of follow up in dSSc who received rituximab (gain of 12 [7.5:14] % vs loss of 1.5 [−16.8; 2.5], (p = 0.003)). Pooled analysis of 53 patients (40 literature patients and 13 from personal series) showed significant improvement of median mRSS from 18 [8; 32] at baseline to 9 [4; 18] at M6 (p = 0.007), 13 [8; 18] at M12 (p = 0.008) and 10 [4; 16] at the last follow-up (p = 0.0002). FVC increased from 71% [66; 80] at baseline to 84% [75; 90] at M12 (p = 0.001). DLCO increased from 58% [39; 65] at M0 to 63% [53; 78] at M12 (p = 0.04). Conclusion: Our personal data and pooled literature analysis suggest the efficacy of rituximab in the subset of diffuse SSc in particular in skin and interstitial disease involvements. The safety of rituximab seems to be reasonable and similar to previous data in other autoimmune diseases.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T15:24:46Z
2024-01-25T12:37:32Z